SNY - Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant | Benzinga
French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its insulin production site in Frankfurt, Germany.
The site in Frankfurt’s Hoechst district is known for producing the company’s insulin brand, Lantus.
Also Read: Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M.
This move comes after initial plans to shift Lantus production to France were reconsidered.
The decision ...